A Study on the Safety of Deucravacitinib Exposure in Pregnant Women and Their Offspring (NCT06710470)

🧪 Interventions in This Study

• Deucravacitinib (DRUG)
• Systemic psoriasis medications (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (1 Sites)

• Bristol-Meyers Squibb — Lawrenceville, New Jersey

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Psoriasis

• Deucravacitinib Adherence Study — Winston-Salem, North Carolina
• An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects — San Diego, California
• Psoriasis Longitudinal Assessment and Registry — Birmingham, Alabama
• Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 — Birmingham, Alabama
• Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis — Birmingham, Alabama
• Prevention of Cardiovascular Disease and Mortality in Patients With Psoriasis or Psoriatic Arthritis — Scottsdale, Arizona

Explore by condition: All Psoriasis clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.